RZLT
Rezolute, Inc.
Key Financials
Net Income
$-74412000
↓ 8.7%
Operating Income
$-79894000
↓ 13.4%
Total Liabilities
$13.4M
↑ 13.9%
EPS (Diluted)
$-0.98
↑ 26.3%
Shareholders' Equity
$162.1M
↑ 34.0%
Total Assets
$175.5M
↑ 32.2%
Cash & Equivalents
$94.1M
↑ 33.7%
Operating Cash Flow
$-69075000.00
↓ 20.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/2/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/11/2026 | View on SEC |
| 8-K | 5/4/2026 | View on SEC |
| 4 | 3/31/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 8-K | 3/24/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RZLT |
| Company Name | Rezolute, Inc. |
| CIK | 1509261 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | NV |
| Phone | 650-206-4507 |